Supportive treatments

Emerging treatment approaches for myeloma-related bone disease.
Gavriatopoulou M et al. Expert Rev Hematol. 2017 Jan 17. doi: 10.1080/17474086.2017.1283213. [Epub ahead of print].

Comparison if the addition of multilevel vertebral augmentation to conventional therapy will improve the outcome of patients with multiple myeloma.
Audat ZA et al. Scoliosis Spinal Disord. 2016 Dec 29;11:47. doi: 10.1186/s13013-016-0107-6. eCollection 2016.

 

Complications of myeloma and its treatments

Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. Snowden JA et al. Br J Haematol. 2017 Jan 20. doi: 10.1111/bjh.14514. [Epub ahead of print]. The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry. Beijers AJ et al. Ann Hematol. 2017 Jan 23. doi: 10.1007/s00277-017-2927-8. [Epub ahead…

Current treatments

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Durie BG et al. Lancet. 2016 Dec 22. pii: S0140-6736(16)31594-X. doi: 10.1016/S0140-6736(16)31594-X. [Epub ahead of print]. Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly…

Guidelines for screening and management of late and long-term consequences of myeloma and its treatment

These guidelines, produced by the British Society of Haematology (BSH) and the UK Myeloma Forum (UKMF), highlight the late and long-term effects of myeloma and its treatments, and summarise the national consensus for the screening and management of these effects.

Snowden et al. (2017) British Journal of Haematology

General

Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib. Berenson A et al. Ann Hematol. 2016 Dec 8. [Epub ahead of print]. Practical Considerations in Managing Relapsed Multiple Myeloma. Agarwal A et al. Clin Lymphoma Myeloma Leuk. 2016 Nov 23. pii: S2152-2650(16)30873-4. doi: 10.1016/j.clml.2016.11.010. [Epub ahead of print]. Effects of Stress Appraisal on the Quality of Life of Adult Patients with Multiple Myeloma and Their Primary Family…

Supportive treatments

Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study. Hansen PB et al. Support Care Cancer. 2016 Dec 13. [Epub ahead of print]. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Di Nisio M et al. Cochrane Database Syst Rev. 2016 Dec…

Complications of myeloma and its treatments

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Jones JR et al. Blood Cancer J. 2016 Dec 9;6(12):e506. doi: 10.1038/bcj.2016.114. Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study. Hinduja A et al. PLoS One. 2016 Nov 30;11(11):e0166627. doi: 10.1371/journal.pone.0166627. eCollection 2016. Bullous skin lesions in a patient…

Current treatments

Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Skerget M et al. Radiol Oncol. 2016 May 12;50(4):402-408. eCollection 2016. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma – a phase II…